Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN; up to $7.1M in payments plus royalties

Ocugen, Inc.

Celairis gets exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand and ASEAN markets.
Ocugen receives an upfront fee plus development/milestone payments up to $7.1M, including $6.1M tied to the upfront payment and Phase 3 liMeliGhT top-line data expected in Q1 2027.
Separate $1.0M milestone payable on Therapeutic Goods Administration approval in Australia; Ocugen also gets a high single-digit percentage royalty on net sales and 50% of gross profits.
Ocugen retains sole manufacturing rights and the parties target a supply agreement within 90 days; territory covers an estimated 725 million people and can expand by mutual agreement.
Ocugen calls it the third strategic regional partnership for OCU400; U.S. BLA and EU MAA filings are planned after the Q1 2027 topline readout.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.